BioGaia

Regulatory Filings • Apr 21, 2008

Press Release 21 April 2008

BioGaia signs agreement for Belgium and Luxembourg

BioGaia has signed a distribution agreement with the Belgium company NeoCare which gives NeoCare rights to sell BioGaia's Probiotic drops and tablets in Belgium and Luxembourg. The products will be sold under BioGaia's trademark.

NeoCare is a pharmaceutical company, operational in Belgium, building a unique partnership philosophy in the choice of products which are generally recognised for their absolute and proven top quality.

"The agreement with NeoCare proves that we have a very competitive product portfolio appealing to companies with focus on pharmacies and health care stakeholders", says PR President BioGaia AB.

"The products will be the first probiotic product-range in Belgium and Luxembourg, offered under the special pharmaceutical form of drops (indicated for infants) and chewable tablets", says Jef Hus, General Manager NeoCare.

Latest press releases from BioGaia:

2008-03-19	Notice of Annual General Meeting of BioGaia
2008-02-20	BioGaia signs new agreement with Ferring Pharmaceuticals
2008-02-13	Year-end report

For additional information contact:

Peter Rothschild, President, telephone: +46 8 - 555 293 00, Jan Annwall, Executive vice President, telephone: +46 8 - 555 293 00 -------------------------------------------------------------------------------------------------------------------------------------------------------

BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri (Reuteri), which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Small Cap list of the Nordic Stock Exchange in Stockholm. www.biogaia.com